Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 months with Recor Medical’s Paradise Ultrasound Renal Denervation System

Palo Alto, CA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two clinical studies presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference this week: data from the Global Paradise System (GPS) Registry demonstrated a 19.6 mmHg reduction in office systolic blood pressure at six months with the Paradise™ Ultrasound Renal Denervation (uRDN) system; and the pooled analysis of data from the RADIANCE global clinical trial program showed a sustained reduction of 15.7 mmHg in office systolic blood pressure at 24 months. The Paradise uRDN system is a device-based adjunctive therapy for patients with uncontrolled and resistant hypertension whose blood pressure cannot be properly managed with lifestyle changes and medication.

19.6 mmHg BP Reduction in 6-Month Data from the GPS Registry
The GPS Registry is a real world, all comers, prospective and retrospective registry being conducted in nine countries outside of the United States, designed to assess the long-term safety and effectiveness of the Paradise uRDN system when used according to its labeling. Presented by Dr. Karl Fengler, Heart Center, Leipzig, the results included the first prospective analysis of data from 212 patients. Office systolic blood pressure at six months post-procedure was reduced by 19.6 mmHg and home systolic blood pressure was reduced by 14.4 mmHg compared to baseline (all p